Cost-effectiveness study of the microbiological diagnosis of tuberculosis using geneXpert MTB/RIF®

Rodríguez, 2012, Situación de la tuberculosis en España. Casos de tuberculosis declarados a la Red Nacional de Vigilancia Epidemiológica en 2010, Bol Epidemiol Sem, 20, 26 Guía de Práctica Clínica sobre el Diagnóstico, el Tratamiento y la Prevención de la Tuberculosis, 2009, Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad González-Martín, 2010, Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis, Enferm Infecc Microbiol Clin, 28, 297.e1, 10.1016/j.eimc.2010.02.006 Davies, 2008, The diagnosis and misdiagnosis of tuberculosis, Int J Tuberc Lung Dis, 12, 1226 Steingart, 2013, Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD009593.pub2 Vassall, 2011, Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis, PLoS Med, 8, e1001120, 10.1371/journal.pmed.1001120 2011 2013 Menzies, 2012, Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation, PLoS Med, 9, e1001347, 10.1371/journal.pmed.1001347 Drummond, 2015 Hughes, 2012, The cost effectiveness of nucleic acid amplification techniques for the diagnosis of tuberculosis, Respir Med, 106, 300, 10.1016/j.rmed.2011.10.005 Roos, 1998, Cost-effectiveness of the polymerase chain reaction versus smear examination for the diagnosis of tuberculosis in Kenya: a theoretical model, Int J Tuberc Lung Dis, 2, 235 Catanzaro, 2000, The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial, JAMA, 283, 639, 10.1001/jama.283.5.639 Lawn, 2011, Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study, PLoS Med, 8, e1001067, 10.1371/journal.pmed.1001067 Moreira, 2009, Weighing harm in therapeutic decisions of smear-negative pulmonary tuberculosis, Med Decis Mak, 29, 380, 10.1177/0272989X08327330 Dorman, 2012, Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey, PLoS ONE, 7, e43307, 10.1371/journal.pone.0043307 Armand, 2011, Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens, J Clin Microbiol, 49, 1772, 10.1128/JCM.02157-10 DOCM, 2012, 28987 Caminero, 2010, Treatment of tuberculosis according to the different pattern of resistance, Med Clin (Barc), 134, 173, 10.1016/j.medcli.2008.12.024 Chang, 2012, Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis, J Infect, 64, 580, 10.1016/j.jinf.2012.02.012 Kind, 1999 Holland, 2009, Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection, Am J Respir Crit Care Med, 179, 1055, 10.1164/rccm.200901-0153OC Tan, 2008, Cost-effectiveness of LTBI treatment for TB contacts in British Columbia, Value Health, 11, 842, 10.1111/j.1524-4733.2008.00334.x Khan, 2002, Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States, N Engl J Med, 347, 1850, 10.1056/NEJMsa021099